Robert W. Shaw

Director Robert W. Shaw bought 1,750 shares of ULBI at $5.67; stock down 36.5% from 52-week high, cluster buy detected

Robert W. Shaw purchased 1,750 shares at $5.67, expanding his holdings by 2.5% to 71,000 shares. The stock has declined significantly: down 36.5% from its 52-week high of $9.13 and off 14.2% over the past 30 days. His same-ticker history shows mixed timing results—one prior buy delivered a 90d return of +41.0%, but two others yielded negative 90d returns. A cluster pattern is present: 2 other insiders also bought within the past 14 days, suggesting coordinated conviction among board members or management at depressed price levels. Fundamentals show the company is unprofitable (net income $-1.2M on revenue of $43.4M) with a stretched valuation (P/E of 58.00), creating context for why insider accumulation at these prices merits investor attention. The convergence of multiple insiders purchasing into weakness, combined with significant recent stock decline, warrants closer examination of whether this reflects non-public confidence or is a marker of the profitability challenges evident in the latest financials.

Director Robert W. Shaw bought 4,000 shares of ULBI at $5.49; concurrent cluster of 3 other insider buys in 14 days.

Robert W. Shaw, a director, purchased 4,000 shares at $5.49, increasing his holdings to 69,250 shares. The transaction occurred as part of a cluster pattern—3 other insiders also bought ULBI within the past 14 days. Notably, Shaw's cross-ticker track record shows 0 of 2 prior buys were well-timed at the 90-day mark, with an average 90-day return of -16.3%. At ULBI specifically, his prior two purchases (in 2024 and 2023) similarly failed to precede upward price movement, returning -1.1% and -31.4% respectively over 90 days. The current stock price of $5.52 is -56.4% from its 52-week high of $12.66, though it has risen +25.4% over the past 30 days. The company trades at a P/E of 17.25 with modest fundamentals: $50.7M in latest quarterly revenue, $1.9M net income, and +3.7% annual revenue growth.

Director Robert W. Shaw buys 2,500 shares of ULBI at $7.91; stock down 39.6% from 52-week high.

Robert W. Shaw, a Director of Ultralife Corporation, purchased 2,500 shares at $7.91 on 2024-11-12, bringing his holdings to 65,250 shares. The purchase occurred as ULBI trades 39.6% below its 52-week high and down 12.7% over 30 days, suggesting a buy during a period of weakness. However, Shaw's cross-ticker track record shows only 1 prior buy with an average 90-day return of -31.4% and a 90-day win rate of 0.00%, indicating his prior open-market purchases have not proven well-timed. At the same ticker (ULBI), his prior 2023 buy also produced a -31.4% 90-day return, establishing a consistent pattern of poor timing on this specific stock. The company's fundamentals show annual revenue growth of +20.3% and a P/E of 14.81, though the market cap is only $133,015,440.00, suggesting a smaller-cap name.